Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing locally delivered antimicrobials for infectious diseases. Its lead program is Nu-3, a Bisphosphocin® antibacterial being studied for topical treatment of mildly infected diabetic foot ulcers, alongside earlier-stage pipeline compounds and a patent portfolio covering its technologies.
Business
Share of revenueNu-3 and related formulations being developed for topical treatment of infected wounds.
Bisphosphocin®-based small-molecule compounds targeting bacterial infections and AMR.
Earlier-stage infectious disease programs under preclinical and clinical evaluation.
Issued patents and pending applications covering products and technologies in major markets.
Customers
The company does not yet sell approved products, so its immediate “customers” are not commercial buyers but regulators, clinical investigators, and future healthcare providers that would use its therapies if approved. Its eventual end users are patients with infectious diseases, especially those with diabetic foot ulcers and other bacterial infections where local treatment may be useful. The commercial buyer, if development succeeds, would likely be hospitals, wound-care providers, and other healthcare systems purchasing prescription therapeutics.
FDA and comparable agencies review the clinical package needed to advance Nu-3 and other candidates.
Hospitals, clinics, and researchers conduct the safety, dose, and efficacy studies required for development.
Future commercial buyers for topical anti-infective treatments used in diabetic foot ulcers and similar infections.
End users who would receive locally delivered antimicrobials if the products reach market.
Strategy
The company’s strategy is to advance Nu-3 through clinical development, starting with safety and dose-response work and then moving toward comparative studies needed for later-stage trials. It is also refining earlier pipeline compounds to identify the best indications for non-clinical and clinical evaluation, while relying on its patent estate to support future commercialization options. Success depends on regulatory approval and the ability to fund multi-year development programs.
Nu-3 is the lead asset and the main path to any future product revenue.
Earlier-stage compounds need clear clinical targets before costly development.
Patent coverage supports exclusivity and future partnering or commercialization.
Geography
Lakewood-Amedex is headquartered in University Park, Florida and is organized in the United States. Its business is currently centered on U.S.-based research, development, and regulatory activity, while its patent coverage is described as extending into major pharmaceutical markets. Because it has no approved products or product revenue, geography today mainly affects where development work is performed and where future commercialization rights may be pursued.
Risks
The company faces the typical risks of a clinical-stage biotech: development failure, regulatory delay, and uncertainty over whether any candidate will ever reach commercialization. It also depends on external financing to fund operations, and its value is highly sensitive to clinical outcomes, patent protection, and the medical need for new antimicrobials in resistant infections.
The company has no product revenue and must fund development through external capital sources.
Exposure: Corporate operations and clinical programs
Nu-3 and other candidates must prove safety and efficacy in human studies before commercialization.
Exposure: Lead program and pipeline candidates
Advancement depends on FDA or comparable authorities approving trial results and later marketing applications.
Exposure: All product candidates
AMR targets are scientifically difficult, and new therapies can be undermined by resistance or better alternatives.
Exposure: Bisphosphocin® platform and infectious disease pipeline
Patent scope, validity, and enforceability are central to future exclusivity and partnering value.
Exposure: 68 issued patents and 36 pending applications
Accounting
Judgemental itemsClinical and preclinical costs are expensed as incurred, so trial timing drives quarter-to-quarter volatility.
Impact: Affects operating loss and comparability across periods
Equity awards and related compensation can materially affect G&A and reported losses.
Impact: Affects operating expenses and dilution analysis
Recent financing instruments may involve conversion features and fair value judgments.
Impact: Affects interest expense, equity, and potential dilution
With no product revenue, management’s funding assumptions are central to financial statement interpretation.
Impact: Affects risk assessment and disclosure emphasis
Similar listed companies
Publicly listed companies with a comparable business focus.
Lakefront Biotherapeutics NV
LKFT · Pharmaceutical Preparations
Lakefront Biotherapeutics NV is a biotechnology company focused on discovering, acquiring, and advancing medicines for serious diseases with high unmet medical need.
Nuo Therapeutics, Inc.
AURX · Surgical & Medical Instruments & Apparatus
Citius Pharmaceuticals, Inc.
CTXR · Pharmaceutical Preparations
Nu-Med Plus, Inc.
NUMD · Surgical & Medical Instruments & Apparatus
Nuvectis Pharma, Inc.
NVCT · Pharmaceutical Preparations
MiMedx Group, Inc
MDXG · Surgical & Medical Instruments & Apparatus
MIMEDX Group develops and commercializes regenerative biologic products used by clinicians to treat chronic wounds, burns, and surgical applications.
Last updated: 16/06/2026